Based on the data from the Phase 1b trial of its first-generation drug candidate, RGLS4326, the Company has decided to prioritize the development of its other product candidates. RGLS stock dips 25% today. It was trading at $0.75 in the previous session. Today it’s trading at $0.56. Following discussions with the FDA, the company has decided that advancing its next-generation compound, RGLS8429, over the development of its current program, is more compelling than continuing with the current program.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.